Xaira’s War on Trial-and-Error Drug Development

“Nothing excites me as much as the potential for AI,” Xaira CEO Marc Tessier-Lavigne tells Bloomberg Intelligence analyst Sam Fazeli on this episode of the Vanguards of Health Care podcast. They explore how artificial intelligence could cut drug development timelines in half and triple clinical suc…

AVS’ Toland on Next Lithotripsy Launch

“IVL in general is an enabler for physicians to do very complex procedures — it’s simple, it’s easy to use and it’s safe. So even a physician that doesn’t have a lot of experience doing complex cases can now treat patients that they previously weren’t treating,” AVS Pulse Chairman Mark Toland tells…

Halle Tecco on AI, Boom-Bust Cycles and Building Better Care

“I wake up every day wanting to make health care better,” says Halle Tecco, founder of Rock Health and author of Massively Better Healthcare. Tecco joins Bloomberg Intelligence analyst Jonathan Palmer on this episode of the Vanguards of Health Care podcast to reflect on digital health’s evolution —…

Highridge Goes Private to Expand Differentiated Offering in Spine

“Being privately held and being a pure play spine company has given us the focus, the resourcing and the investment we need to, to really take this thing and make it hum,” Highridge’s CEO Rebecca Whitney says about the 7th largest spine company. In this Vanguards of Health Care episode, Whitney sit…

Dexcom Aims to Expand CGM Benefits to All Diabetic Patients and Beyond

“We’re going to continue to drive innovation across the entire product portfolio, which also includes how we manufacture sensors,” Dexcom CEO Jake Leach tells Bloomberg Intelligence, outlining the company’s strategy to expand the use of continuous glucose monitors to more diabetic patients and beyo…

AliveCor’s Priya Abani Uses Amazon Experience to Democratize ECG Tech

“We’re empowering health-care providers with unprecedented clinical depth in a compact portable form factor,” AliveCor CEO Priya Abani says about the development of its AI-enabled electrocardiogram (ECG) sensors, which provide medical-grade heart data anytime and anywhere. In this Vanguards of Heal…

John Maraganore Reflects on the Long Game of RNAi and Drug Innovation

“I suspect that RNAi-based medicines will approach, rival, maybe even exceed what we’ve seen with monoclonal antibodies historically,” says John Maraganore, the CEO of JMM Innovations and founding CEO of Alnylam. He joins Bloomberg Intelligence’s senior pharmaceutical analyst Sam Fazeli to reflect …

Carlsmed Personalizes Spine with AI

“One of our busy surgeons said, when they do an aprevo procedure, it’s a boring day in the OR and that’s actually a good thing,” Carlsmed’s CEO Mike Cordonnier tells Bloomberg Intelligence, as he explains how the use of AI technology is the future for spine procedures. In this Vanguards of Health C…

Precision Cardiology With Cytokinetics

“Now we’re seeing how there are new medicines that act directly on the heart itself and less on downstream consequences of heart disease,” says Robert Blum, president and CEO of Cytokinetics. On this episode of Vanguards of Health Care, Blum speaks with Bloomberg Intelligence analyst Andrew Galler …

Transcarent’s Bet on AI and the End of Healthcare Scarcity

“Health care creates friction everywhere — copays, approvals, pre-authorizations — and none of that matters when someone you love needs help right now,” says Glen Tullman, CEO of Transcarent, in his return to the Vanguards of Health Care podcast to explain why speed, access and simplicity are exist…